Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting

Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting

<br/><strong>Objectives: </strong>The soluble fms‐like tyrosine kinase‐1 (sFlt‐1) to placental growth factor (PlGF) ratio is generally elevated some time before and at the clinical onset of pre‐eclampsia. The PROGNOSIS study validated a sFlt‐1/PlGF ratio cut‐off of ≤ 38 to rule out...

Full description

Bibliographic Details
Main Authors:	Zeisler, H, Llurba, E, Chantraine, F, Vatish, M, Staff, A, Sennström, M, Olovsson, M, Brennecke, S, Stepan, H, Allegranza, D, Schoedl, M, Grill, S, Hund, M, Verlohren, S
Format:	Journal article
Language:	English
Published:	Wiley 2019

Similar Items

Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia
by: Zeisler, H, et al.
Published: (2016)

Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.
by: Zeisler, H, et al.
Published: (2016)

Implementation of the sFlt‐1/PlGF ratio for prediction and diagnosis of pre‐eclampsia in singleton pregnancy: implications for clinical practice
by: Stepan, H, et al.
Published: (2015)

Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice.
by: Stepan, H, et al.
Published: (2015)

The sflt-1/plgf ratio test in pre-eclampsia: an economic assessment for the UK
by: Vatish, M, et al.
Published: (2016)

Circulating soluble fms-like tyrosine kinase-1 is placentally derived in normal pregnancy: first in vivo evidence
by: Cerdeira, AS, et al.
Published: (2019)

Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1/placental growth factor ratio ≤38: secondary analysis of the Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia
by: Cerdeira, AS, et al.
Published: (2021)

Predictive accuracy of soluble FMS-like tyrosine kinase-1/placental growth factor ratio for preeclampsia in Japan: a systematic review
by: Yamazaki, T, et al.
Published: (2020)

Associations Between Soluble fms‐Like Tyrosine Kinase‐1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia
by: Roxanne Hastie, et al.
Published: (2022-08-01)

Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study
by: Ahmed M. Abbas, et al.
Published: (2018-07-01)

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis
by: Geoff K Frampton, et al.
Published: (2016-11-01)

The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
by: Kifle, MM, et al.
Published: (2022)

The ratio of soluble fms–like tyrosine kinase 1 to placental growth factor predicts time to delivery and mode of birth in patients with suspected preeclampsia- a secondary analysis of the INSPIRE trial
by: Palma Dos Reis, CR, et al.
Published: (2024)

The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
by: Meron M. Kifle, et al.
Published: (2022-06-01)

Placental apoptosis in pre-eclampsia
by: P. A. Khovhaeva, et al.
Published: (2016-12-01)

Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study.
by: Birgitte Mitlid-Mork, et al.
Published: (2020-01-01)

Soluble fms-like tyrosine kinase 1 and placental growth factor ratio for predicting preeclampsia in elderly gravida
by: Vorapong Phupong, et al.
Published: (2020-04-01)

Placental Pathology in Severe Pre-eclampsia and Eclampsia
by: Kamala Ojha, et al.
Published: (2018-06-01)

One step closer to a cure for preeclampsia? Boosting the natural affinity of VEGF (vascular endothelial growth factor) to sFlt (soluble fms-like tyrosine kinase)-1
by: Cerdeira, AS, et al.
Published: (2020)

Serum placental growth factor and soluble fms-like tyrosine kinase-1 in preeclamptic women at their third trimester of pregnancy
by: Nesreen Nasser, et al.
Published: (2020-12-01)

Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: The SaPPPhirE Study.
by: Agrawal, S, et al.
Published: (2017)

An Examination of the Effect of Aspirin and Salicylic Acid on Soluble Fms-like Tyrosine Kinase-1 Release from Human Placental Trophoblasts
by: Jiawu Zhao, et al.
Published: (2024-01-01)

Angiogenic factors: potential to change clinical practice in pre-eclampsia?
by: Cerdeira, A, et al.
Published: (2017)

Soluble Fms-like tyrosine cinase 1 (sFLt-1) and antibody against AT1-receptor in preclempsia a comparison in a blind study design
by: Verlohren, S, et al.
Published: (2008)

Placental morphology in pre-eclampsia and eclampsia and the likely role of NK cells
by: Maham Akhlaq, et al.
Published: (2012-01-01)

Diagnostic Accuracy of Different Soluble fms-Like Tyrosine Kinase 1 and Placental Growth Factor Cut-Off Values in the Assessment of Preterm and Term Preeclampsia: A Gestational Age Matched Case-Control Study
by: Evelyn A. Huhn, et al.
Published: (2018-11-01)

Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study
by: Teresa M. MacDonald, et al.
Published: (2018-08-01)

Differences Ratio Level Soluble FMS-Like Tyrosine Kinase-1 and Placental Growth Factor Early And Late Onset on Preeclampsia and Normal Pregnancy
by: Ria Andina, et al.
Published: (2018-06-01)

Maternal serum soluble fms-like tyrosine kinase-1–to–placental growth factor ratio distinguishes growth-restricted from non–growth-restricted small-for-gestational-age fetusesAJOG Global Reports at a Glance
by: Prithi Rajiv, MD, et al.
Published: (2024-02-01)

IFPA senior award lecture: Making sense of pre-eclampsia - Two placental causes of preeclampsia?
by: Redman, C, et al.
Published: (2014)

Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) and Autoantibodies Against the AT1-Receptor in Preeclampsia in a Matched Pair, Blinded, Study Design.
by: Verlohren, S, et al.
Published: (2008)

Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
by: Sathya Selvarajan, et al.
Published: (2019-10-01)

Placental debris, oxidative stress and pre-eclampsia.
by: Redman, C, et al.
Published: (2000)

Placental and Renal Pathways Underlying Pre-Eclampsia
by: Paraskevi Eva Andronikidi, et al.
Published: (2024-02-01)

Tumor Necrosis Factor Inhibitor Use Increases Birthweight in Pregnant Women With Rheumatoid Arthritis Independently of the Soluble Fms‐Like Tyrosine Kinase‐1/Placental Growth Factor Ratio
by: Cornelia H. Quaak, et al.
Published: (2024-04-01)

Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia
by: Lissette C. Sánchez-Aranguren, et al.
Published: (2018-03-01)

IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia?
by: Redman, C, et al.
Published: (2014)

Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study.
by: Herse, F, et al.
Published: (2009)

Relationship between Androgens and Vascular and Placental Function during Pre-eclampsia
by: Lara M. Fernandes, et al.
Published: (2024-02-01)

Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
by: Robert W Powers, et al.
Published: (2010-10-01)